Loading stock data…
Recursion Pharmaceuticals (RXRX)
$3.44-0.19 (-5.23%)
Market ClosedLast close Sep 8
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Recursion Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.44 with a market capitalization of $1.7B. Wall Street consensus targets $7.22 (6 analysts), implying a +109.8% move over the next 12 months. The stock is currently near its 52-week low of $2.77, remaining 5.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +109.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.30M↓ | $35.35M↑ | $4.98M↓ | $19.10M↑ | $14.82M |
| Gross Profit | -$6.19M↓ | $21.08M↑ | -$9.70M↓ | -$1.06M↑ | -$7.01M |
| Operating Income | -$128.50M↓ | -$108.33M↑ | -$172.20M↑ | -$176.23M↑ | -$191.37M |
| Net Income | -$117.50M↓ | -$108.12M↑ | -$162.25M↑ | -$171.90M↑ | -$202.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.62%
Volume
Today's trading volume
14.89M
Recent News
2 Beaten-Down Stocks to Avoid Right Now
Don't catch a falling knife.
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making